Mitomycin-induced thrombotic thrombocytopenic purpura: possible successful treatment with vincristine and cyclophosphamide.
The findings and management of a patient with the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura (TTP) is reported. Hyperreactivity of the cytotoxic suppressor T-cell was found. Vincristine and cyclophosphamide reversed the hematologic and renal dysfunction after administration of antiplatelet agents and plasma infusion had failed to do so.
Durand
J M
JM
Department of Internal Medicine, Hôpital Sainte-Marguerite, Marseille, France.
Lefèvre
P
P
D000230:Adenocarcinoma / Q000188:drug therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects*; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy; D010949:Plasma; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D050378:T-Lymphocytes, Regulatory / Q000473:pathology; D013988:Ticlopidine / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
D016685:Mitomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013988:Ticlopidine; D005472:Fluorouracil